JP2017501137A - Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 - Google Patents

Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 Download PDF

Info

Publication number
JP2017501137A
JP2017501137A JP2016535646A JP2016535646A JP2017501137A JP 2017501137 A JP2017501137 A JP 2017501137A JP 2016535646 A JP2016535646 A JP 2016535646A JP 2016535646 A JP2016535646 A JP 2016535646A JP 2017501137 A JP2017501137 A JP 2017501137A
Authority
JP
Japan
Prior art keywords
seq
antibody
biomarker
wnt pathway
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016535646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501137A5 (enExample
Inventor
アン エム． カポウン
アン エム． カポウン
チュン チャン
チュン チャン
Original Assignee
オンコメッド ファーマシューティカルズ インコーポレイテッド
オンコメッド ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オンコメッド ファーマシューティカルズ インコーポレイテッド, オンコメッド ファーマシューティカルズ インコーポレイテッド filed Critical オンコメッド ファーマシューティカルズ インコーポレイテッド
Publication of JP2017501137A publication Critical patent/JP2017501137A/ja
Publication of JP2017501137A5 publication Critical patent/JP2017501137A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016535646A 2013-12-02 2014-12-02 Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定 Pending JP2017501137A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361910663P 2013-12-02 2013-12-02
US61/910,663 2013-12-02
US201461975339P 2014-04-04 2014-04-04
US61/975,339 2014-04-04
PCT/US2014/068097 WO2015084808A1 (en) 2013-12-02 2014-12-02 Identification of predictive biomarkers associated with wnt pathway inhibitors

Publications (2)

Publication Number Publication Date
JP2017501137A true JP2017501137A (ja) 2017-01-12
JP2017501137A5 JP2017501137A5 (enExample) 2018-01-18

Family

ID=53274023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016535646A Pending JP2017501137A (ja) 2013-12-02 2014-12-02 Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定

Country Status (9)

Country Link
EP (1) EP3077546A4 (enExample)
JP (1) JP2017501137A (enExample)
CN (1) CN105829547A (enExample)
AU (1) AU2014357354A1 (enExample)
CA (1) CA2931975A1 (enExample)
HK (1) HK1223657A1 (enExample)
MX (1) MX2016007066A (enExample)
TW (1) TW201610168A (enExample)
WO (1) WO2015084808A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532720A (ja) * 2015-09-16 2018-11-08 トビラ セラピューティクス， インコーポレイテッド 線維症の治療のためのセニクリビロック併用療法
JP2021143843A (ja) * 2020-03-10 2021-09-24 学校法人杏林学園 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法
WO2023113013A1 (ja) * 2021-12-17 2023-06-22 国立大学法人京都大学 疾患発症の可能性の推定を行う遺伝子の選別方法及び疾患発症の可能性を推定する方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US20180223372A1 (en) * 2015-08-03 2018-08-09 Oncomed Pharmaceutical, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
US11267876B2 (en) 2016-10-26 2022-03-08 Leap Therapeutics, Inc. Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
CN106990245B (zh) * 2017-04-05 2018-07-31 东南大学 检测pitx1表达量的试剂在制备胃癌预后评估试剂盒中的应用
CN110835372B (zh) * 2019-11-06 2020-12-01 上海健康医学院 一种靶向Frizzled7单克隆抗体及其制备方法与应用
CN111735949B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒
CN115337400A (zh) * 2021-05-13 2022-11-15 中国科学院分子细胞科学卓越创新中心 诊断和治疗肿瘤的试剂及其用途
CN113293212A (zh) * 2021-06-17 2021-08-24 深圳华因康基因科技有限公司 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用
WO2024189200A1 (en) * 2023-03-15 2024-09-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Cancer stratification and treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway
JP2012503990A (ja) * 2008-09-26 2012-02-16 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JP2003518920A (ja) * 1999-07-02 2003-06-17 カイロン コーポレイション 新規なヒト遺伝子および遺伝子発現産物
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
EP1549144A4 (en) * 2002-10-04 2010-01-06 Univ California METHOD FOR THE TREATMENT OF CANCER BY INHIBITION OF THE WNT SIGNALING LINE
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1697415A1 (en) 2003-11-12 2006-09-06 Biogen Idec MA Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1945754B1 (en) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TW200819463A (en) 2006-09-08 2008-05-01 Genentech Inc Wnt antagonists and their use in the diagnosis and treatment of Wnt-mediated disorders
WO2008039071A2 (en) * 2006-09-29 2008-04-03 Agendia B.V. High-throughput diagnostic testing using arrays
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2242762B1 (en) 2008-01-18 2015-12-16 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
US20120053079A1 (en) * 2009-03-06 2012-03-01 University Of South Alabama Methods and compositions for the diagnosis, prognosis and treatment of cancer
US20130045209A1 (en) 2010-01-12 2013-02-21 Oncomed Pharmaceuticals, Inc. WNT-Binding Agents and Uses Thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503990A (ja) * 2008-09-26 2012-02-16 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US20100169025A1 (en) * 2008-10-10 2010-07-01 Arthur William T Methods and gene expression signature for wnt/b-catenin signaling pathway

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GURNEY A, ET AL.: "Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 29, JPN6018030347, 17 July 2012 (2012-07-17), pages 11717 - 11722, ISSN: 0003990551 *
長崎 光一, 三木 義男: "遺伝子発現解析と乳癌の個別化癌治療", ＰＨＡＲＭＡ ＭＥＤＩＣＡ, vol. 第２４巻，第１１号, JPN6018030349, 2006, pages 47 - 51, ISSN: 0003990552 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532720A (ja) * 2015-09-16 2018-11-08 トビラ セラピューティクス， インコーポレイテッド 線維症の治療のためのセニクリビロック併用療法
JP2021143843A (ja) * 2020-03-10 2021-09-24 学校法人杏林学園 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法
JP7593584B2 (ja) 2020-03-10 2024-12-03 学校法人杏林学園 腫瘍細胞マーカー、および腫瘍細胞を検出または回収する方法
WO2023113013A1 (ja) * 2021-12-17 2023-06-22 国立大学法人京都大学 疾患発症の可能性の推定を行う遺伝子の選別方法及び疾患発症の可能性を推定する方法

Also Published As

Publication number Publication date
EP3077546A4 (en) 2017-04-26
EP3077546A1 (en) 2016-10-12
MX2016007066A (es) 2016-09-08
WO2015084808A4 (en) 2015-08-13
CA2931975A1 (en) 2015-06-11
WO2015084808A1 (en) 2015-06-11
HK1223657A1 (zh) 2017-08-04
AU2014357354A1 (en) 2016-06-09
CN105829547A (zh) 2016-08-03
TW201610168A (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
JP2017501137A (ja) Ｗｎｔ経路インヒビターに関連する予測バイオマーカーの同定
TWI506037B (zh) 捲曲結合劑類及彼等之用途
US9598497B2 (en) RSPO3 binding agents and uses thereof
US20150132301A1 (en) Combination Therapy for Treatment of Cancer
AU2013271515A1 (en) Binding agents that modulate the Hippo pathway and uses thereof
US20160319034A1 (en) Met-binding agents and uses thereof
US20170266276A1 (en) Combination Therapy For Treatment of Cancer
US20170247465A1 (en) Combination therapy for treatment of cancer
US9168300B2 (en) MET-binding agents and uses thereof
US20170023576A1 (en) Notch3 antibodies and uses thereof
US20170022289A1 (en) Methods for treating cancer with notch1 antiboides
US20160304968A1 (en) Identification of Predictive Biomarkers Associated With WNT Pathway Inhibitors
JP7599716B2 (ja) がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
WO2017095918A2 (en) Methods for treating cancer using rspo3 antagonists
US20180223372A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2016201199A1 (en) Identification of predictive biomarkers associated with wnt pathway inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180806

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190306